Articles tagged with Prostate Cancer
After prostate cancer surgery, patients often experience penile shortening due to anatomical changes. The study found that this change is shortest 10 days post-surgery but recovers to normal values within 12 months.
Researchers at UC San Francisco and Kaiser Permanente have identified genetic predictors of normal prostate-specific antigen (PSA) levels in healthy men. This information can be used to improve the accuracy of PSA-based prostate cancer screening tests.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
A study by the NRG Oncology Radiation Therapy Oncology Group found that adding antiandrogen therapy to radiation therapy can reduce the incidence of metastasis, death from prostate cancer, and overall deaths in patients with recurrent prostate cancer. The study showed a significant improvement in survival rates for patients treated wit...
A new treatment regimen combining hormonal therapy with radiation treatment significantly improves the average long-term survival of men with recurrent prostate cancer who have had their prostate gland removed. The study found that this regimen also reduces the frequency of spread of the cancer, improving patient outcomes.
Researchers found consistent differences in prostate shape and transitional zone between men with and without prostate cancer. The findings suggest a potential biomarker for disease diagnosis and aggressiveness.
A large-scale study led by Dr. Laurent Azoulay found no association between androgen deprivation therapy and an increased risk of Alzheimer's disease in patients with advanced prostate cancer. The study analyzed data from nearly 31,000 men with nonmetastatic prostate cancer over a 27-year period.
Researchers at the University of Adelaide have identified a new microRNA that promotes cancer metastasis, leading to the development of a potential blood test for early detection. The discovery also reveals new targets for drugs that may inhibit cancer spread.
A new MRI scan test may improve diagnosis and reduce unnecessary biopsies for men with suspected prostate cancer. The test detected aggressive cancers correctly in 93% of cases, while avoiding over-diagnosis by 5%. Men without cancer or harmless cancers were also correctly identified.
Researchers found that a prostate-specific antigen (PSA) nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy identifies men prior to PSA failure who are at high risk for dying early. This marker can help identify men in need of more aggressive treatment, potentially making it curable.
A recent randomized trial compared active monitoring, surgery, and radiation therapy for localized prostate cancer. The study's results may be limited by differences in the active monitoring protocol and advances in treatment methods.
A new study published in the Journal of Urology found that men with prostate cancer who experience high levels of emotional distress are more likely to choose aggressive treatment options, such as surgery and radiation therapy. The researchers suggest that providing clearer information about prognosis and strategies for dealing with an...
A landmark study reveals that men with a family history of prostate cancer and the BRCA2 gene fault have a more aggressive form of prostate cancer. The study shows that these cancers are genetically similar to advanced cancers, explaining why BRCA2 patients have poor outcomes.
Researchers at the University Health Network have discovered a genetic fingerprint that explains why up to 30% of men with localized prostate cancer develop aggressive disease after radiotherapy or surgery. This finding could help clinicians personalize effective treatments from diagnosis, leading to improved cure rates.
A new study finds that prostate cancer treatment rates dropped by 42% due to changes in screening recommendations, but treatment rates among those diagnosed remained high. Low-risk patients with limited life expectancy can now opt for surveillance instead of treatment.
Scientists at Roswell Park Comprehensive Cancer Center have identified gatekeeper genes that allow prostate cancer to progress and resist treatment. The study highlights opportunities to prevent or reverse this process, offering new insights into lineage plasticity and its application in other types of cancers.
Researchers at Scripps Florida have identified a novel signaling circuit driving therapy resistance in advanced prostate cancer. Targeting the components of this circuit, such as the NF-kB pathway and microRNA miR-196b-3p, shows promise in blocking the expression of stem cell transcription factors that fuel aggressive tumor growth.
A new UCL-led phase III clinical trial found that vascular-targeted photodynamic therapy (VTP) can effectively kill cancer cells while preserving healthy tissue. Around half of patients treated with VTP went into complete remission, compared to 13.5% in the control group.
A study of three genes associated with prostate cancer found that men with inherited mutations are more likely to develop aggressive forms and die earlier. The study suggests that germline mutations in these genes can be used to predict risk for lethal prostate cancer.
A 15-year study of prostate cancer patients found little difference in mortality between those screened annually and those not screened. However, the data suggest that personalized screening strategies could identify men at higher risk of death from other diseases.
A DNA methylation biomarker called PITX2 has been identified as a reliable predictor of prostate cancer recurrence. The study found that patients with high PITX2 methylation levels were at significantly increased risk for recurrence. This breakthrough could lead to more personalized treatment strategies for prostate cancer patients.
A panel of urologists and radiologists recommends using prostate MRI and MRI targeted biopsy for patients with suspected prostate cancer despite a prior negative biopsy. The recommended guidelines aim to improve detection rates, accuracy, and treatment options for these patients.
A novel imaging agent, Zr-89-Df-IAB2M, has been shown to detect metastasis of prostate cancer in both bone and soft tissue lesions with high accuracy. The agent targets PSMA on the exterior of prostate cancer cells, allowing for faster and more accurate detection than conventional methods.
Researchers report good results in patients with metastatic prostate cancer using bipolar androgen therapy (BAT), which alternately floods and starves the body of testosterone. The treatment has been safe and effective, with PSA levels falling, tumors shrinking, and some men showing a complete remission.
Researchers develop a novel method to track an antibody targeting the hormone receptor pathway involved in prostate cancer. The technique uses PET scans to detect and monitor disease progression in real-time, enabling personalized treatment guidance.
A study by King's College London found that black men face barriers to participating in prostate cancer research, including mistrust of researchers and a preference for traditional medicines. The researchers suggest community-driven engagement and dissemination of reliable information as ways to improve inclusion.
A new study by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. The computer model uses medical images to reproduce the growth patterns of prostate cancer on the anatomy of a patient's prostate.
A team of researchers has developed a new prediction model that uses crowdsourced data from 550 international researchers to provide more accurate prognosis for patients with metastatic castration-resistant prostate cancer. The model, called ePCR, was developed through a collaboration between 16 institutions and used a computational le...
The University of California, Irvine has received a $1.2 million grant to develop more effective ways for prostate cancer patients and their physicians to customize treatment. The two-year clinical study will use patient-reported disease burden and tumor biomarkers to evaluate the effectiveness of treatment.
A new study by researchers at the University of Victoria and Australia's National Drug Research Institute found a statistically significant dose-response relationship between alcohol intake and risk of prostate cancer. Current drinkers who consumed high volumes had an increased risk, even at low-volume drinking levels.
Researchers at The Wistar Institute found TRAP1 increases tumor cell proliferation and invasion while providing a potential new therapeutic target for prostate cancer. TRAP1 overexpression combined with PTEN loss led to aggressive invasive prostate cancer in mice.
Researchers have discovered that the NAALADL2 molecule, which indicates more aggressive prostate cancer, can also be used to guide treatments. This new marker has the potential to distinguish between slow-growing and fast-growing prostate cancers.
A study of 2386 men with localized prostate cancer found that second opinions did not affect treatment choice or quality of care. Men who sought second opinions due to dissatisfaction with their initial urologist were less likely to receive definitive treatment.
Following the USPSTF recommendation against population-based PSA screening, median biopsy volume per urologist decreased by 29% and RP volume decreased by 16%. Prostate cancer diagnostic and therapeutic practice patterns have shifted significantly.
A special issue of Future Oncology examines the latest breakthroughs in prostate cancer imaging, including multiparametric MRI and PET imaging. The issue aims to provide a comprehensive overview of the field's current state and future directions.
A SWOG study found widespread detection bias in prostate cancer biopsies, affecting younger, healthier men and those with family history or elevated PSA levels. Biases led to inconsistent results on risk factors, highlighting the need for rigorous data analysis and caution against assumptions.
Researchers at Indiana University have discovered a connection between the genetic mechanisms that trigger Ewing's sarcoma and prostate cancer. This finding could lead to the development of new treatments for patients with both diseases.
African American men have higher incidence and mortality rates of prostate cancer due to genetic factors and socioeconomic disparities. MNX1 is a new oncogene identified as more active in African American prostate cancer, which can lead to improved diagnostic tools and treatment approaches.
A new report suggests that well over half of American men with non-aggressive prostate cancer could choose to monitor their disease instead of seeking immediate radiation treatment or surgery. Active surveillance relies on regular blood tests, physical exams, and periodic biopsies to screen for tumor growth before therapy is considered.
A new study found that androgen deprivation therapy for prostate cancer may be associated with an increased risk of dementia, particularly among older men. The study analyzed electronic medical records data and found a significant association between ADT use and dementia development.
A new retrospective study found that men with prostate cancer treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as those whose testosterone levels are not tampered with. The study used deidentified records from Stanford Medicine's clinical-research data warehouse and aggregated several f...
A new study published in International Journal of Cancer found that men with prostate cancer who used snus were at increased risk of premature death. Snus users had higher levels of nicotine and exposure to carcinogens compared to never-users, suggesting a potential link between snus use and prostate cancer progression.
A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone found no significant survival gains compared to the placebo arm. Custirsen blocks clusterin production, which is involved in carcinogenesis and treatment resistance.
A five-year review of over 275,000 visits at UT Southwestern Medical Center showed that PSA testing remained unchanged despite revised guidelines discouraging its use. The study found slight increases in PSA levels after the guidelines were revised, but these had little clinical impact on treatment or results.
Researchers mapped patterns of prostate cancer recurrence using C-11 choline PET imaging and multiparametric MRI, identifying sites of recurrence that can be targeted for radiation therapy. Nearly two-thirds of men had recurrence limited to the pelvis, a potentially treatable area.
Researchers found that delivering higher doses of radiation over a shortened period was safe and associated with lower costs for patients with favorable-risk prostate cancer. The hypofractionated radiation therapy schedule demonstrated comparable quality of life outcomes to conventional radiation therapy.
NRG-RTOG 0232 study found no significant difference in 5-year progression-free survival between external beam radiation therapy plus brachytherapy and brachytherapy alone. The treatment combination also resulted in fewer late genitourinary effects, mostly noted in the brachytherapy only arm.
Researchers developed a new way to identify aggressive prostate cancer patients by analyzing their tumor's genetic pathways. The study found three subtypes of prostate tumors, with one subtype showing high disease progression and poor clinical outcomes.
A recent study suggests that the digital rectal exam (DRE) is no longer necessary for prostate cancer screening due to its limited effectiveness and potential risks. The DRE has been shown to capture an additional small population of men with significant prostate cancer, but it also subjects a large number of men to unnecessary tests.
Researchers at Brigham and Women's Hospital found that PSA failure increases the risk of death by 1.6-fold in healthy men, but not those with comorbidities like heart disease or stroke. The study suggests healthy men should be informed about clinical trials showing reduced PSA failure benefits.
Researchers found that CHD1-depleted human prostate cancer cells are hypersensitive to DNA breaks and chemotherapeutic drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy.
Researchers at UT Southwestern Medical Center developed a novel MRI method that can detect low levels of zinc ions to differentiate between healthy and malignant prostate tissue. This technique has the potential to serve as a biomarker for tracking prostate cancer progression.
Rates of early prostate cancer have continued to drop since the USPSTF recommendation, with localized/regional-stage incidence rates declining by 6-19% from 2011 to 2013. The decrease is attributed to changes in PSA testing rates and potentially unknown risk factors.
A recent study published in Nature Genetics has identified 45 noncoding genes associated with prostate cancer development and progression. These genes, known as noncoding RNA, play a key role in activating the disease process.
Researchers at Umeå University found that men with very high-risk prostate cancer treated at hospitals with a high proportion of radical local treatment had only half the mortality risk compared to those treated at low-proportion hospitals. Radical local therapy may prolong life for these patients.
Researchers developed a computational approach to identify individualized targets for therapy by analyzing patient-specific data and mapping complex networks of gene and protein interactions. The study provides insights into the mechanisms behind resistance to anti-androgen therapies and offers a tool for prioritizing effective drugs.
Researchers at Brigham and Women's Hospital found that African-American men treated with hormone therapy had a 77% higher risk of death compared to non-African American men. The study analyzed over 7,000 patients and found that the increased mortality rate was not due to prostate cancer.
A new scheme improved prostate cancer prognosis by grouping men into 5 strata based on clinical measurements like PSA level, disease stage, and tumor grade. This method performed better in predicting cancer death compared to the current risk stratification system.
A new study published in The Journal of Urology found no association between phosphodiesterase type 5 inhibitors (PDE-5i) and reduced risk of developing prostate cancer. PDE-5i use was also not linked to lower or higher grade cancer types.
Scientists at Newcastle University have identified a group of molecules that can be targeted to slow tumor growth in prostate cancer patients. The research found that testosterone changes these molecules, making cancer cells more likely to survive and spread.